超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國MAP Pharmaceuticals
美國MAP制藥使用專有的吸入技術(shù)，以提高治療效果和成熟的商業(yè)吸引力，同時盡量減少藥物通過其已知的安全性，有效性和商業(yè)化的歷史資本化的風(fēng)險。LEVADEX? 治療成人急性偏頭痛

MAP Pharmaceuticals uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
The clinical development programs at MAP Pharmaceuticals include proprietary product candidates that address large market opportunities. The most advanced product candidate is LEVADEX? orally inhaled migraine therapy.

Our technologies enable us to develop proprietary drug candidates for delivery via the respiratory tract to more effectively treat both local respiratory and systemically treatable diseases. We create inhalable drug particles with the specific physical and chemical characteristics to facilitate efficient pulmonary delivery. We believe this will result in medicines that are more appropriate for the intended indication. Our product candidates are designed to offer several benefits to patients compared to alternative therapies, including: quicker symptom relief, longer-lasting therapeutic benefit at lower doses, shorter administration time, enhanced safety profile and convenient, non-invasive delivery.